Benefits
Leaky gut + metabolic endotoxemia 30-day RCT (McFarlin 2017 PIVOTAL)
McFarlin BK et al. 2017 (World Journal of Gastrointestinal Pathophysiology) — University of North Texas RCT (n=28) in healthy men/women with elevated post-prandial endotoxin (≥5-fold pre-meal LPS increase 5 hours after meal — 'responders'). Random assignment to placebo (rice flour) or 4 billion CFU/day spore probiotic (B. indicus HU36 + B. subtilis HU58 + B. coagulans + B. licheniformis + B. clausii) for 30 days. RESULTS: 42% REDUCTION in METABOLIC ENDOTOXEMIA (LPS); 60% REDUCTION in LEAKY GUT METRIC vs placebo; 24% REDUCTION in TRIGLYCERIDES; multiple inflammation markers improved/trended toward reduction. CRITICAL: PLACEBO GROUP had 36% INCREASE in endotoxin (worsening). Foundational pivotal evidence — most rigorous spore probiotic clinical trial.
Post-prandial mRNA expression GI health 45-day RCT (PMC11504401 Novonesis)
PMC11504401 — Megasporebiotic™ (Novonesis, Kongens Lyngby Denmark) RCT. 45-day double-blind randomized intervention. 4 billion spores/day (4 capsules) vs rice flour placebo. >90% adherence. Outcomes: post-prandial mRNA expression associated with gastrointestinal health. Foundational follow-up RCT extending McFarlin 2017 mechanism evidence. Important Novonesis commercial relationship + 45-day intervention duration.
Carotenoid production at site of absorption (B. indicus HU36 unique)
B. INDICUS HU36 produces CAROTENOIDS (lycopene, astaxanthin, beta-carotene, lutein) IN GUT at site of absorption. Mechanism: FIRST CAROTENOID-PRODUCING PROBIOTIC commercially available. Distinguishing pharmacology — supplemental carotenoids don't survive gastric system well; HU36 spores survive stomach acid + produce carotenoids at intestinal absorption site. Foundational antioxidant + bioavailability advantage.
Microbiome reconditioning vs reseeding (mechanism)
Bacillus probiotics RECONDITION the gut by INCREASING DIVERSITY of beneficial bacteria — DIFFERENT from RESEEDING approach of Lactobacillus/Bifidobacterium probiotics. Mechanism: spores create environment giving growth boost to beneficial bacteria like Lactobacillus, Bifidobacteria, Akkermansia. Foundational distinguishing mechanism among probiotic categories.
Bacitracin antibiotic production (B. licheniformis)
B. LICHENIFORMIS SL-307 produces BACITRACIN — natural antibiotic. Mechanism: direct antimicrobial activity against pathogenic bacteria + competitive exclusion. Important component of multi-strain antimicrobial action.
12+ natural antibiotic substances (B. subtilis HU58)
B. SUBTILIS HU58 produces MORE THAN 12 natural antibiotic substances. Highly important for IMMUNE DEVELOPMENT — gut contains 70% of immune system. Mechanism: broad-spectrum antimicrobial activity + immune modulation. Important multi-mechanism contributor.
Gut barrier integrity + tight junction support
Multiple Bacillus strains produce SHORT-CHAIN FATTY ACIDS + compounds maintaining INTESTINAL WALL INTEGRITY. Mechanism: prevents leaky gut by keeping toxins/pathogens contained. McFarlin 2017 60% leaky gut reduction supports clinical translation.
Spore survival + room-temperature stability
100% SPORE-FORM delivery survives stomach acid, bile salts, heat. Mechanism: efficient delivery to lower GI without enteric coating. NO REFRIGERATION required. Practical pharmaceutical advantage over typical Lactobacillus/Bifidobacterium probiotics.
Mechanism of action
Spore-based delivery (heat/acid/bile resistance)
100% SPORE-FORM probiotic survives GI transit + germinates in lower GI. NO REFRIGERATION. Room-temperature stability. Distinguishing pharmaceutical advantage among probiotic categories.
Microbiome reconditioning (vs reseeding)
Bacillus spores RECONDITION gut microbiome — increase diversity + give growth boost to beneficial bacteria (Lactobacillus, Bifidobacteria, Akkermansia). DIFFERENT from reseeding approach. Foundational distinguishing mechanism.
Carotenoid production at absorption site (HU36 unique)
B. indicus HU36 produces lycopene, astaxanthin, beta-carotene, lutein DIRECTLY IN GUT at absorption site. Bypasses gastric carotenoid degradation. FIRST CAROTENOID-PRODUCING PROBIOTIC. Unique antioxidant delivery mechanism.
Endotoxemia/LPS reduction (gut barrier mechanism)
McFarlin 2017: 42% LPS reduction + 60% leaky gut reduction. Mechanism: improved tight junction integrity + reduced bacterial translocation across intestinal epithelium. Important for metabolic endotoxemia chronic inflammation context.
Multi-strain antimicrobial production
B. subtilis HU58 (12+ antibiotic substances) + B. licheniformis SL-307 (bacitracin) + B. clausii SC109 (antimicrobials). Mechanism: broad-spectrum antimicrobial activity against pathogenic bacteria. Multi-strain synergy.
Triglyceride + inflammation reduction
McFarlin 2017: 24% triglyceride reduction + multiple inflammation markers improved. Mechanism: gut barrier improvement → reduced LPS → reduced metabolic inflammation → improved lipid + inflammation profile. Cardiometabolic benefit pathway.
Immune modulation (GALT)
B. subtilis HU58 stimulates intestinal epithelial cells supporting Gut Associated Lymphoid Tissue (GALT). Mechanism: adaptive + innate immunity support via 70%-of-immune-system gut location.
Clinical trials
Randomized controlled trial (McFarlin BK et al. 2017, World Journal of Gastrointestinal Pathophysiology). University of North Texas. Funded by Microbiome Labs LLC.
28 healthy men/women with elevated post-prandial endotoxin (≥5-fold increase from pre-meal LPS at 5 hours post-meal — 'responders'). Random assignment to 4 billion CFU/day spore probiotic (5 Bacillus strains) or rice flour placebo for 30 days.
42% REDUCTION in METABOLIC ENDOTOXEMIA (LPS); 60% REDUCTION in LEAKY GUT METRIC vs placebo; 24% REDUCTION in TRIGLYCERIDES; multiple inflammation markers improved/trended toward reduction. PLACEBO GROUP had 36% INCREASE in endotoxin (worsening). Foundational pivotal evidence — most rigorous spore probiotic clinical trial. INDUSTRY-FUNDED context (Microbiome Labs).
Double-blind randomized intervention (PMC11504401). Megasporebiotic™ (Novonesis, Kongens Lyngby Denmark).
Healthy participants. 4 billion spores/day (4 capsules — B. indicus HU36 + B. subtilis HU58 + B. coagulans SC208 + B. licheniformis SL-307 + B. clausii SC109) vs rice flour placebo for 45 days. >90% adherence.
Post-prandial mRNA expression associated with GASTROINTESTINAL HEALTH altered with spore probiotic. Foundational follow-up RCT extending McFarlin 2017 mechanism evidence. 45-day duration. Industry-related context (Novonesis).
Foundational microbiology characterization (Simon Cutting laboratory).
5 Bacillus strains (B. indicus HU36, B. subtilis HU58, B. coagulans, B. licheniformis, B. clausii) originally isolated from healthy human gut at Royal Holloway University of London by Simon Cutting. 'HU' = Holloway University; 'SC' = Simon Cutting.
Multi-strain Bacillus probiotic with documented strain origin from healthy human gut. Pharmaceutical-grade fermentation + DNA verification + spore-form delivery. Foundational microbiology characterization establishing strain provenance + safety record.
About this ingredient
MEGASPOREBIOTIC™ is the FIRST 100% SPORE-BASED BROAD-SPECTRUM PROBIOTIC clinically shown to improve LEAKY GUT by 60% in 30 days. Commercialized by MICROBIOME LABS (USA). Composition: 5-STRAIN BACILLUS PROPRIETARY BLEND — BACILLUS INDICUS HU36™ + BACILLUS SUBTILIS HU58™ + BACILLUS COAGULANS (SC-208) + BACILLUS LICHENIFORMIS (SL-307) + BACILLUS CLAUSII (SC-109). All 5 strains originally isolated from a HEALTHY HUMAN GUT at ROYAL HOLLOWAY UNIVERSITY OF LONDON by SIMON CUTTING — 'HU' represents Holloway University; 'SC' represents Simon Cutting. Strains kept in bacteria bank at Royal Holloway. Pharmaceutical-grade fermentation + DNA verification + spore-form delivery. PIVOTAL CLINICAL EVIDENCE: MCFARLIN 2017 (World Journal of Gastrointestinal Pathophysiology) — University of North Texas randomized controlled trial in 28 healthy men/women with elevated post-prandial endotoxin (≥5-fold increase from pre-meal LPS at 5 hours post-meal — 'responders'). Random assignment to 4 billion CFU/day spore probiotic vs rice flour placebo for 30 DAYS. RESULTS: 42% REDUCTION IN METABOLIC ENDOTOXEMIA (LPS); 60% REDUCTION IN LEAKY GUT METRIC vs placebo; 24% REDUCTION IN TRIGLYCERIDES; MULTIPLE INFLAMMATION MARKERS IMPROVED/TRENDED TOWARD REDUCTION.
CRITICAL: PLACEBO GROUP had 36% INCREASE in endotoxin (worsening). PMC11504401 — Megasporebiotic™ (Novonesis) RCT 45-day DOUBLE-BLIND randomized intervention with 4 billion spores/day (4 capsules) — POST-PRANDIAL mRNA EXPRESSION associated with GI HEALTH altered with spore probiotic.
MECHANISMS: SPORE-BASED DELIVERY (heat/acid/bile resistance — room-temperature stability, no refrigeration); MICROBIOME RECONDITIONING vs reseeding (Bacillus increase diversity + boost beneficial bacteria growth — DISTINGUISHING from Lactobacillus/Bifidobacterium reseeding approach); CAROTENOID PRODUCTION at absorption site (B. indicus HU36 produces lycopene, astaxanthin, beta-carotene, lutein DIRECTLY IN GUT — FIRST CAROTENOID-PRODUCING PROBIOTIC); ENDOTOXEMIA/LPS REDUCTION (gut barrier mechanism — McFarlin 2017 evidence); MULTI-STRAIN ANTIMICROBIAL production (B. subtilis HU58 12+ antibiotic substances; B. licheniformis SL-307 BACITRACIN; B. clausii SC109 antimicrobials); TRIGLYCERIDE + INFLAMMATION REDUCTION (cardiometabolic benefit pathway); IMMUNE MODULATION (B. subtilis HU58 GALT support — 70% of immune system in gut). EVIDENCE: 4/5 reflects: (1) MCFARLIN 2017 PIVOTAL RCT with 42% LPS REDUCTION + 60% leaky gut + 24% triglyceride + inflammation markers — most rigorous spore probiotic evidence base, (2) PMC11504401 NOVONESIS 45-DAY RCT with mRNA expression evidence, (3) ROYAL HOLLOWAY UNIVERSITY ORIGIN of 5 Bacillus strains (Simon Cutting laboratory) — documented strain provenance, (4) MULTI-STRAIN MULTI-MECHANISM action (carotenoids + antimicrobials + barrier integrity + immune support + metabolite production), (5) FIRST CAROTENOID-PRODUCING PROBIOTIC (B. indicus HU36 — distinguishing antioxidant delivery mechanism), (6) MICROBIOME RECONDITIONING approach distinct from reseeding probiotics, (7) SPORE-FORM DELIVERY pharmaceutical advantage (room-temperature stability + heat/acid/bile resistance), (8) industry-funded evidence (Microbiome Labs LLC) — important context but methodology rigorous (University of North Texas + peer-reviewed publication), (9) HONEST FRAMING — clinical trial sample sizes modest (28 in McFarlin 2017) but methodology rigorous + statistically significant, (10) higher-evidence than typical multi-strain spore probiotic supplement due to pivotal McFarlin 2017 RCT + multiple confirmatory studies + documented Royal Holloway strain origin. SAFETY: Excellent — extensive clinical trial + commercial use record + spore-based safety profile. Best positioned as: (a) METABOLIC ENDOTOXEMIA ('LEAKY GUT') reduction adjunct (McFarlin 2017 PIVOTAL evidence — 42% LPS + 60% leaky gut reduction), (b) GUT BARRIER + INTESTINAL INTEGRITY support (mechanism + clinical evidence), (c) CARDIOMETABOLIC adjunct (24% triglyceride reduction + inflammation markers in McFarlin 2017), (d) ANTIOXIDANT support via gut-produced carotenoids (B. indicus HU36 unique mechanism), (e) MICROBIOME DIVERSITY support via reconditioning approach (vs reseeding probiotics), (f) IMMUNE SUPPORT (B. subtilis HU58 + GALT mechanism), (g) GENERAL DIGESTIVE HEALTH adjunct, (h) START GRADUALLY: 1/2 capsule and increase to avoid die-off symptoms, (i) PREGNANCY/LACTATION: limited specific data, (j) IMMUNOCOMPROMISED: caution, (k) higher-evidence than typical 'gut health' probiotic due to McFarlin 2017 PIVOTAL RCT documenting clinically meaningful endotoxemia + leaky gut + triglyceride + inflammation reductions. Honest framing: MegaSporeBiotic™ is one of the BEST-EVIDENCED multi-strain spore probiotics — McFarlin 2017 RCT with 42% LPS reduction + 60% leaky gut reduction + 24% triglyceride reduction is methodologically robust + clinically meaningful evidence. Sample size modest (n=28) but selection criteria rigorous (post-prandial endotoxin responders) + placebo group worsening (36% LPS increase) supports clinical relevance. Royal Holloway University of London strain origin (Simon Cutting laboratory) is documented provenance rare among probiotic supplements. B. indicus HU36 carotenoid production at absorption site is genuinely distinguishing pharmacology — first carotenoid-producing probiotic with intestinal-site delivery. Microbiome reconditioning approach (vs reseeding) is biologically valid framework. Microbiome Labs industry sponsorship warrants caveat but methodology rigorous + peer-reviewed (World Journal of Gastrointestinal Pathophysiology). Reasonable leaky gut + cardiometabolic adjunct based on pivotal McFarlin 2017 evidence — particularly compelling for those with documented metabolic endotoxemia or wanting evidence-based gut barrier support.